Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

391 ARTÍCULOS , VIENDO DEL 151 AL 165

EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease

Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn DJ, Colosimo C, Fanciulli A, Ferreira J, Gasser T, Grandas F, Kanovsky P, Kostic V, Kulisevsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Schrag A, Seppi K, Taba P, Vidailhet M.

Eur J Neurol. 2013 Jan;20(1):16-34. doi: 10.1111/ene.12022.

Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study

Weintraub D, Papay K, Siderowf A; Parkinson's Progression Markers Initiative.

Neurology. 2013 Jan 8;80(2):176-80. doi: 10.1212/WNL.0b013e31827b915c.

Movement disorders in 2012: Advancing research towards novel therapeutic approaches

McFarland NR, Okun MS.

Nat Rev Neurol. 2013 Feb;9(2):70-1. doi: 10.1038/nrneurol.2012.265. Epub 2013 Jan 8.

Neurorehabilitation in Parkinson disease

Archibald N, Miller N, Rochester L.

Handb Clin Neurol. 2013;110:435-42. doi: 10.1016/B978-0-444-52901-5.00037-X.

The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models

Sato H, Kato T, Arawaka S.

Rev Neurosci. 2013;24(2):115-23. doi: 10.1515/revneuro-2012-0071.

Parkinson's disease in the nuclear age of neuroinflammation

Nolan YM, Sullivan AM, Toulouse A.

Trends Mol Med. 2013 Mar;19(3):187-96. doi: 10.1016/j.molmed.2012.12.003. Epub 2013 Jan 11.

Oxidative damage to macromolecules in human Parkinson disease and the rotenone model

Sanders LH, Timothy Greenamyre J.

Free Radic Biol Med. 2013 Sep;62:111-120. doi: 10.1016/j.freeradbiomed.2013.01.003. Epub 2013 Jan 15.

Bilateral globus pallidus internus deep brain stimulation in Parkinson's disease with periodic limb movement disorder

Klassen BT, Lyons MK, Evidente VG.

Turk Neurosurg. 2013;23(1):104-6. doi: 10.5137/1019-5149.JTN.4198-11.1.

Sigma receptor modulators: a patent review

Collina S, Gaggeri R, Marra A, Bassi A, Negrinotti S, Negri F, Rossi D.

Expert Opin Ther Pat. 2013 May;23(5):597-613. doi: 10.1517/13543776.2013.769522. Epub 2013 Feb 7.

Which dyskinesia scale best detects treatment response?

Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, Stacy MA, Nutt JG, Tanner CM, Urkowitz A, Jaglin JA, Ge S.

Mov Disord. 2013 Mar;28(3):341-6. doi: 10.1002/mds.25321. Epub 2013 Feb 6.

Trophic factor gene therapy for Parkinson's disease

Kordower JH, Bjorklund A.

Mov Disord. 2013 Jan;28(1):96-109. doi: 10.1002/mds.25344.

A meta-analysis of the relationship of the Parkin p.Val380Leu polymorphism to Parkinson's disease

Zhang Y, Wang ZZ, Sun HM.

Am J Med Genet B Neuropsychiatr Genet. 2013 Apr;162B(3):235-44. doi: 10.1002/ajmg.b.32138. Epub 2013 Feb 21.

Instruments for holistic assessment of Parkinson's disease

Martinez-Martin P.

J Neural Transm (Vienna). 2013 Apr;120(4):559-64. doi: 10.1007/s00702-013-1005-1. Epub 2013 Mar 10.

Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes

Bajaj N, Hauser RA, Grachev ID.

J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1288-95. doi: 10.1136/jnnp-2012-304436. Epub 2013 Mar 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias